Dual-mode SERS-based lateral flow assay strips for simultaneous diagnosis of SARS-CoV-2 and influenza a virus

Nano Convergence

Table 1 Clinical assay results for SARS-CoV-2 and influenza A virus using RT-PCR, commercial LFA, and dual-mode SERS-LFA strips performed on 39 patient samples

Sample	No.	Ct value (ORF1 RNA)	Group	LFA (P/N)	Dual-mode SERS-LFA
Sample	No.	Ct value (ORF1 RNA)	Group	LFA (P/N)	Ratio (TL1/CL)	P/N
SARS-CoV-2 Positive	P1	18.87	< 20	P	1.601	P
	P2	22.78	20–25	P	0.215	P
	P3	22.9		P	0.285	P
	P4	23.47		P	0.54	P
	P5	23.9		N	0.096	P
	P6	24.59		P	0.209	P
	P7	24.68		P	1.138	P
	P8	24.95		P	0.107	P
	P9	25.12	25–30	P	0.113	P
	P10	25.83		P	0.133	P
	P11	26.57		P	0.236	P
	P12	26.65		P	0.123	P
	P13	26.87		N	0.064	P
	P14	27.34		P	0.072	P
	P15	29.52		N	0.067	P
	P16	29.69		P	0.292	P
	P17	29.7		N	0.012	N
	P18	30.07	> 30	P	0.077	P
	P19	30.45		N	0.142	P
	P20	30.77		N	0.029	N
	P21	31.25		N	0.042	N
	P22	32.38		N	0.022	N
	P23	32.83		N	0.108	P
	P24	33.09		N	0.075	P
	P25	33.88		N	0.018	N
	P26	33.96		N	0.027	N
	P27	34.85		N	0.080	P
	P28	35.92		N	0.145	P

Sample	No.	Ct value ( M RNA)	Group	LFA (P/N)	Dual-mode SERS-LFA
Sample	No.	Ct value ( M RNA)	Group	LFA (P/N)	Ratio (TL2/CL)	P/N
Influenza A virus Positive	P1	25	25–30	P	0.073	P
	P2	25.67		P	0.082	P
	P3	25.67		P	0.335	P
	P4	27.67		N	0.230	P
	P5	32.67	> 30	P	0.099	P
	P6	33.67	> 30	N	0.082	P

Sample	No.	Ct value	Group	LFA (P/N)	Dual-mode SERS-LFA
Sample	No.	Ct value	Group	LFA (P/N)	Ratio (TL1/CL)	Ratio (TL2/CL)	P/N
Negative	N1	N/A	Negative	N	0.018	0.016	N
	N2	N/A		N	0.029	0.027	N
	N3	N/A		N	0.027	0.012	N
	N4	N/A		N	0.022	0.017	N
	N5	N/A		N	0.011	0.027	N